DBV Technologies Shares Fall 4% Mid-Day Amid Profit-Taking
DBV Technologies sees a 4% decline mid-day this Friday, November 28, with shares dropping to 2.40 euros from 2.50 euros the previous day. This correction follows a spectacular 267% rise over the past year, driven by advancements in its Viaskin Peanut clinical program.
Current Market Dynamics
The share price of the French biotech company has decreased by 4% to 2.40 euros at mid-day this Friday, while the CAC 40 index has risen by 0.2% to 8,115 points. Trading volumes remain modest with only 0.19% of capital traded. This decline follows a weekly drop of 3.03%, but is part of a positive quarterly trend with a 51.71% increase over three months. Over the past year, the stock has quintupled, gaining 267%, significantly outperforming the Paris index which only rose by 13.61% over the same period. This technical correction appears as profit-taking after a particularly intense bullish sequence. Technical analysis reveals a stock now very close to its 50-day moving average set at 2.38 euros. The neutral RSI at 51 suggests no strong overbought or oversold signals. Bollinger Bands frame the price between a support at 2.26 euros and a resistance at 2.64 euros, indicating contained volatility in the short term. The 200-day moving average, positioned at 1.70 euros, confirms a fundamentally bullish trend with a gap of more than 40% compared to the current price. The MACD indicator shows neutral values with a line at -0.06 and a histogram close to zero. Fundamentally, DBV Technologies announced in mid-November the completion of the last patient visit in the phase III VITESSE trial evaluating its Viaskin Peanut patch in children aged 4 to 7 years, with preliminary results expected in the fourth quarter of 2025. The company has a cash reserve of $69.8 million as of the end of September, sufficient to fund operations until the third quarter of 2026. Recent capital movements show the interest of institutional investors: Suvretta Capital Management has crossed the 5% threshold while Goldman Sachs has also exceeded this level, demonstrating the attractiveness of the case despite medium-term financing challenges.
